敢生物科学

2023年7月22日

5天改变今天上午51 1934年证券交易法的报告日期(日期最早的事件报道):7月19日2023敢生物科学,INC .特拉华州圣地亚哥CA92122注册人的电话号码,包括区号:(858)926 - 7655不适用(前名或前地址,如果改变了自去年报告。)检查适当的框下面如果表单公布文件是为了同时满足申请注册人在任何的义务(seeGeneral指令由以下条款。下面):☐☐☐☐证券注册依照12节(b)的行为:标题的每个类普通股纳斯达克资本市场显示复选标记是否定义的注册人是一家新兴公司在1933年的证券法案405规则(§230.405本章)或规则12 b - 2 1934年证券交易法(§240.12 b - 2本章)。新兴公司☐如果一个新兴公司,表明通过复选标记如果注册人当选不使用扩展的过渡期间,遵守任何新的或修改后的财务会计准则提供依照第13节(a)的交换行为。¨项3.01通知未能满足持续上市规则或标准;转让上市。2023年7月19日,敢生物科学,Inc .(“敢”)收到了一封来自上市资格的部门(以下简称“员工”)的纳斯达克股票市场(Nasdaq)通知敢说,在过去的30个工作日,敢收投标价格的普通股每股低于最低1.00美元持续在纳斯达克资本市场上市要求提出5550年纳斯达克上市规则(a)(2)(“最低投标价格要求”)。纳斯达克信没有直接影响的清单上敢的普通股在纳斯达克资本市场。依照纳斯达克上市规则,敢提供了最初的180日历天,或者直到1月16日2024(“合规日期”),恢复遵守最低投标价格的要求。在任何时间,如果在这段180天时间内,敢收投标价格的普通股至少1.00美元至少10个工作日,除非员工行使自由裁量权来扩展这种为期10天的期间,工作人员将提供敢书面确认符合最低投标价格要求,此事将被关闭。 If Daré does not regain compliance by the Compliance Date, Daré may be eligible for an additional 180 calendar day compliance period. To qualify for such additional compliance period, Daré would have to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and Daré would need to provide written notice of its intention to cure the deficiency during the additional compliance period, by effecting a reverse stock split, if necessary. If Daré is not eligible for the additional compliance period or it appears to the Staff that Daré will not be able to cure the deficiency or if the Staff exercises its discretion to not provide such additional compliance period, the Staff will provide written notice to Daré that its common stock will be subject to delisting. At that time, Daré may appeal the Staff's delisting determination to a Nasdaq Hearing Panel. Daré will monitor the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that Daré will regain compliance with the Minimum Bid Price Requirement or maintain compliance with any of the other Nasdaq continued listing requirements. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DARÉ BIOSCIENCE, INC.